ORAL ETOPOSIDE IN COMBINATION WITH FARNESYLTRANSFERASE INHIBITOR R115777

口服依托泊苷与法呢基转移酶抑制剂 R115777 组合

• 批准号: 7604648
• 负责人: JUDITH KARP
• 金额: $ 0.87万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604648
• 关键词: Adult; Age; Complex; Computer Retrieval of Information on Scientific Projects Database; Cytotoxic agent; Disease; Etoposide; Exhibits; Farnesyl Transferase Inhibitor; Funding; Genomics; Grant; Institution; Oral; Outcome; R115777 (Zarnestra); Research; Research Personnel; Resistance; Resources; Source; Toxin; United States National Institutes of Health; age group; chemotherapy; cytotoxic; genetic profiling; older patient; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The outcome and survival for adults age 70 and older with AML remains poor. Part of this poor response relates to the inability of very elderly patients (age > 75) to tolerate intensive chemotherapy [13-17]. More important, however, is the inherent resistance of these AMLs to the cytotoxic effects of traditional cytotoxic agents [14,17]. The AMLs that arise in the older age group often do so from an antecedent hematologic disorder (mainly MDS) that itself has evolve from a background of toxin exposures. These MDS/AMLS exhibit a complex genetic profile, likely a result of cumulative genomic damage .

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 AML年龄70岁及以上的成年人的结果和生存率仍然很差。这种不良反应的一部分与非常老年患者无法忍受强化化疗的无能为力[13-17]。然而，更重要的是这些AML对传统细胞毒性剂的细胞毒性作用的固有抗性[14,17]。在较老的年龄组中出现的AML通常是由于毒素暴露的背景而发展的先例血液学疾病（主要是MDS）。这些MDS/AML表现出复杂的遗传特征，这可能是累积基因组损伤的结果。